ClinicalTrials.gg
CompletedNCT05827653CHDR2235Updated Dec 13, 2024

MAD Study of NX210c

A Phase 1 interventional study of NX210c and Placebo in Healthy Elderly, sponsored by Axoltis Pharma. Completed at 1 site in Netherlands. Open to participants aged 55 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by Axoltis Pharma · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Study summary

This study will investigate the safety and tolerability of multiple intravenous infusions of NX210c with two ascending doses as well as NX210c pharmacokinetics (PK), and pharmacodynamics (PD) effects in healthy elderly subjects.

Read the detailed description

The prevalence of neurocognitive disorders (NCD), including neurodegenerative diseases (NDDs) such as Alzheimer's disease (AD) is increasing. NDDs are most common and prevalent in elderly people worldwide and cause progressive neuronal dysfunction, toxicities, and death. These diseases lead to an irreversible weakening of all brain functions, including cognitive impairment. There is not one single cause of cognitive impairment but rather several factors that can contribute to trigger or accelerate cognitive decline.

Preclinical in vitro and in vivo data have shown that NX210c exhibits important properties, which may be suitable for the treatment of neurological disorders in humans. (i.e., neuroprotection, neuro-regeneration, synaptic transmission, positive effects on cognition, anti-neuroinflammatory action).

The First In Human Single Ascending Dose study has been completed. In that study, NX210 was administered and well tolerated. The current project is a multiple ascending dose (MAD) study and designed to investigate the safety, tolerability, PK and pharmacodynamics (PD) effects of multiple intravenous infusions of NX210c in two dose levels in healthy elderly subjects.

02

Conditions studied

  • Healthy Elderly
03

In context

Lead sponsor

Axoltis Pharma is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult male or female participants, as determined by the Investigator, based upon a medical evaluation including medical history, physical examination, neurological examination, , MRI, lab tests and .
  • Aged ≥ 55 years, inclusive at screening, and with a maximum weight of 110 kg.
  • (BMI) between 18 and 32 kg/m2, inclusive at screening.

Exclusion criteria

Exclusion Criteria:

  • Evidence of any history, or any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator
  • History of any known neurologic disease, cognitive impairment, or diagnosed decline in cognitive function abnormal related to the age, or history of seizure, (significant) head trauma, loss of consciousness, or significant neuroimaging findings, including but not limited to any previously known or discovered abnormalities on screening brain MRI that evoke neurological diagnosis indicative of abnormality
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Cohort 1_active

    Dose 1 NX210c

    Drug: NX210c

  • Experimental
    Cohort 1_placebo

    Placebo

    Drug: Placebo

  • Experimental
    Cohort 2_active

    Dose 2 (TBC) NX210c.

    Drug: NX210c

  • Experimental
    Cohort 2_placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugNX210c

    3 times a week, for 28 days

  • DrugPlacebo

    3 times a week, for 28 days

06

What researchers measure

Primary outcomes

  1. Severity and incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), suspected unexpected serious adverse reactions (SUSARs)

    Severity and incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), suspected unexpected serious adverse reactions (SUSARs)

    Time frame: Up to 16 days after last dose

07

Study locations

1 site
  • Centre for Human Drug Research
    Leiden, South Holland 2333 CL, Netherlands
08

References and documents

Individual participant data

Plan to share: No — Anonymized subject data to be shared based on reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Apr 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2022
First posted
Apr 25, 2023
StartActual
Dec 5, 2022
Primary completionActual
Apr 29, 2023
CompletionActual
Oct 2, 2023
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05827653
Lead sponsor
Axoltis Pharma
Collaborators
Centre for Human Drug Research, Netherlands
Responsible party
Sponsor
First posted
Apr 25, 2023
Start date
Dec 5, 2022
Primary completion
Apr 29, 2023
Completion
Oct 2, 2023
Last update
Dec 13, 2024

Study contacts

Philip Kremer, MD, PharmD, PhD
principal investigator · Centre For Human Drug Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Axoltis Pharma

Start the discussion